Lisata Therapeutics Inc.
$ 3.56
2.30%
12 Jun - close price
- Market Cap 32,418,800 USD
- Current Price $ 3.56
- High / Low $ 3.64 / 3.40
- Stock P/E N/A
- Book Value 1.20
- EPS -1.86
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.50 %
- ROE -0.91 %
- 52 Week High 5.07
- 52 Week Low 1.81
About
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing and commercializing cellular therapies to reverse disease and/or promote regeneration of damaged tissue. The company is headquartered in Basking Ridge, New Jersey.
Analyst Target Price
$4.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-11 | 2026-03-12 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-27 | 2024-11-12 | 2024-08-12 | 2024-05-09 | 2024-02-29 | 2023-11-02 | 2023-08-14 |
| Reported EPS | -0.3344 | -0.3344 | -0.49 | -0.54 | -0.55 | -0.55 | -0.59 | -0.61 | -0.65 | -0.66 | -0.65 | -0.5 |
| Estimated EPS | 0 | -0.625 | -0.59 | -0.64 | -0.53 | -0.76 | -0.77 | -0.76 | -0.72 | -0.89 | -0.93 | -0.7 |
| Surprise | -0.3344 | 0.2906 | 0.1 | 0.1 | -0.02 | 0.21 | 0.18 | 0.15 | 0.07 | 0.23 | 0.28 | 0.2 |
| Surprise Percentage | None% | 46.496% | 16.9492% | 15.625% | -3.7736% | 27.6316% | 23.3766% | 19.7368% | 9.7222% | 25.8427% | 30.1075% | 28.5714% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LSTA
2026-06-11 07:10:20
Lisata Therapeutics announced the commencement of a tender offer by Kuva Labs Inc. to acquire all outstanding shares of common stock of Lisata Therapeutics at a price of $0.11 per share. The tender offer is scheduled to expire on July 9, 2026, unless extended. The agreement was approved by the boards of directors of both companies.
2026-06-10 18:09:51
Lisata Therapeutics announced that Kuva Acquisition Corp., a subsidiary of Kuva Labs Inc., has commenced a tender offer to acquire all outstanding shares of Lisata common stock. Stockholders will receive $4.00 per share in cash plus one non-tradeable contingent value right (CVR) representing potential additional cash payments of up to $3.00 per share based on milestone achievements. Lisata's Board of Directors unanimously recommends stockholders tender their shares, with the transaction expected to close in Q3 2026, after which Lisata will become a private company.
2026-06-10 11:41:06
Lisata Therapeutics announced that Kuva Labs Inc. has commenced a tender offer to acquire all outstanding shares of Lisata common stock for $4.00 per share in cash, plus a contingent value right (CVR) potentially worth up to an additional $3.00 per share based on milestone achievements. Lisata's Board of Directors unanimously recommends stockholders tender their shares, and the transaction is expected to close in Q3 2026, after which Lisata will become a private company. The offer is subject to financing, which Kuva Labs has not yet secured.
2026-06-10 11:39:36
This SEC filing (Form SC TO-T) details a third-party tender offer by Kuva Acquisition Corp., a subsidiary of Kuva Labs Inc., to purchase all outstanding common shares of Lisata Therapeutics, Inc. for $4.00 per share in cash plus one contingent value right (CVR) that could yield an additional $3.00. The filing incorporates various sections of the Offer to Purchase and related agreements, outlining the terms, conditions, and background of the proposed acquisition. It includes details about the subject company, the offeror, and the financial and legal aspects of the transaction.
2026-06-10 09:36:00
Lisata Therapeutics has agreed to be acquired by Kuva Labs for $4 per share in cash, plus a contingent value right up to an additional $3.00 per share tied to drug development milestones. Lisata shareholders will receive a non-tradeable CVR for potential payments based on enrollment milestones in a Phase 2a glioblastoma trial and New Drug Application filing for certepetide. The transaction, recommended by Lisata's board, is expected to close in Q3 2026, after which Lisata will be delisted from Nasdaq.
2026-06-10 08:39:36
Lisata Therapeutics, Inc. (LSTA) has filed an SC 14D9 recommending shareholders accept a tender offer from Kuva Acquisition Corp., a wholly-owned subsidiary of Kuva Labs Inc. The offer comprises $4.00 per common share in cash upfront, plus one non-tradeable contingent value right (CVR) which could yield an additional $3.00 per share contingent on the achievement of specific milestones related to the development of its product candidate, certepetide. The Board's recommendation is based on a thorough evaluation of financial advisors' opinions, market alternatives, and the company's capital needs, noting the offer represents an attractive premium to historical market prices. This filing also details the negotiation process, background of the offer, and an overview of the financial projections and associated risks.
